Bacteriophage Therapy Summit on March 11-13, 2025 in Boston, United States

2024 has revitalized the bacteriophage field, with over $9 Million invested into BiomX and Locus Bioscience; $24 Million dedicated by BARDA to progress bacteriophage therapies to Phase II trials; and the release of further regulatory guidelines by agencies.

The advancement to the clinic has resulted in a wealth of data available to investigate the function, genetic modification, and safety of bacteriophages. However, the lack of clarity on the pathway to the market with a sustainable and strategic commercial strategy means that biopharma companies need to rethink their business model to ensure they are sustainable.

At the 7th Bacteriophage Therapy Summit, we'll be diving into the regulatory and investment landscape for drug developers, clinical updates showing efficacy, utilizing machine learning, and developing personalized and off-the-shelf therapies to fight AMR in infectious diseases.

URLs:

Tickets: https://go.evvnt.com/2773104-2?pid=10008

Brochure: https://go.evvnt.com/2773104-3?pid=10008

Time: 8:00 AM - 3:45 PM

Prices:

Drug Developer - Conference Only: USD 2599.00,

Drug Developer - Conference + 1 Workshop: USD 3048.00,

Drug Developer - Conference + 2 Workshops: USD 3497.00,

Service and Solution Provider - Conference Only: USD 3299.00,

Service and Solution Provider - Conference + 1 Workshop: USD 3848.00,

Service and Solution Provider - Conference + 2 Workshops: USD 4397.00,

Academic Pricing - Conference Only: USD 2199.00,

Academic Pricing - Conference + 1 Workshop: USD 2548.00,

Academic Pricing - Conference + 2 Workshops: USD 2897.00

Speakers: Amanda Burkardt, Chief Executive Officer, Phiogen, Anna Jacobs, Biologist and Project Officer, BARDA, Carrie-Lynn Furr, Advisory Board Memberx, CARB-X, David Harper, Principal, ThePhageAdviser, Dean Scholl, Chief Scientific Officer, Pylum Bioscience, Deborah Birx, Chief Executive Officer, Armata Pharmaceuticals, Gregorio Iraola, Chief Executive Officer, Kinzbio, Jason Clark, Chief Scientific Officer, NexaBiome, Kevin Neil, Chief Scientific Officer and Co-Founder, TATUM Bioscience, Kristof Van Emelen, Chief Executive Officer, Obulytix, Mark Mendel, Venture Partner, Sozo Ventures, Minmin Yen, Chief Executive Officer, PhagePro, Nancy Tawil, Chief Scientific Officer, Precisio Biotix Therapeutics, Phil Huss, Chief Scientific Officer, Synpha Biosciences, Sofia Corte-Real, Chief Scientific Officer, TechnoPhage, Steven Theriault, Chief Executive Officer, Cytophage, Taylor Penke, Director of Automation and AI, Locus Biosciences